澳门赌搏网站大全

学校澳门赌搏网站大全 网站地图 个人中心 纪委信箱 院长信箱 English

: : 师资队伍 : :

微信/QQ扫一扫转发

您所在的位置:澳门赌搏网站大全  师资队伍  师资队伍  梁宏

梁宏

梁宏 [教授]

联系方式

办公电话:(0773)5846185

手机号码:

电子邮箱:hliang@mailbox.gxnu.edu.cn

办公地址:

基本先容

任职广西科协副主席,省部共建药用资源化学与药物分子工程国家重点实验室主任,广西师范大学博士生导师,兼任南开大学、南京大学无机化学博士生导师和中南大学应用化学博士生导师。研究成果主要发表在Nature CommunicationsAngew Chem Int EdMolecular PharmaceuticsJournal of Medicinal ChemistryEur Chem JChem Comm《中国科学》等国内外权威期刊300余篇, 并被国内外学者在SCI期刊引用约3000次;多次获得广西科技进步一等奖和广西自然科学一等奖授权20项国家发明专利。

研究方向

新型抗肿瘤金属药物和载药体系:

1)细胞迁移机制

2)基于DNA和蛋白质设计新型抗肿瘤金属药物

3) 蛋白质和纳米载药体系

 

社会任职

中国化学会理事

广西化学化工学会理事长

Curr Pharm Des 客座主编

国际刊物《Biomedical Materials》编委

《无机化学学报》(SCI-E期刊)编委

美国科学促进会(AAAS)特邀国际会员

Chemical reviewMol PharmJ Med ChemEur J Med ChemJ Inorg Biochem 等国际权威期刊审稿人

 

讲授课程

生物无机化学

论著专利

3年代表性论文:

1. Yue JP, Zhang Y, Liang WG, Gou XW, Lee P, Liu H, Lyv WQ, Tang WJ, Yang F*, Liang H*, Wu XY*. In Vivo Epidermal Migration Requires Focal Adhesion Targeting of ACF7. Nature Communications. 2016, 7:11692. (综合性顶级期刊)

2. YL Ma, JP Yue, Y Zhang, CZ Shi, M Odenwald, WG Liang, Q Wei, A Goel, XW Gou, J Zhang, SY Chen, WJ Tang, JR Turner, F Yang*,H Liang*, HL Qin*, XY Wu*. ACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamics. Nature Communications. 2017,8: 15375.

3. Chen ZF*, Qin QP, Qin JL, Liu YC, Huang KB, Li YL, Meng T, Zhang GH, Peng Y, Luo XJ, Liang H*. Stabilization of G-quadruplex DNA, inhibition of telomerase activity, and tumor cell apoptosis by organoplatinum(II) complexes with oxoisoaporphine. J Med Chem. 2015; 58: 2159-2179. (药物化学顶级期刊)

4. Chen ZF*, Qin QP, Qin JL, Zhou J, Li YL, Li N, Liu YC, Liang H*. Water-soluble ruthenium(II) complexes with chiral 4-(2,3-Dihydroxypropyl)-formamide oxoaporphine (FOA): in vitro and in vivo anticancer activity by stabilization of G-Quadruplex DNA, inhibition of telomerase activity, and induction of tumor cell apoptosis. J Med Chem. 2015; 58: 4771-4789.

5.Gou Y, Qi JX, Zhang Y, Jiang M, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing anticancer copper(II) pro-drugs based on the nature of cancer cells and human serum albumin carrier IIA subdomain. Molecular Pharmaceutics. 2015, 12: 3597-3609. (药剂学顶级期刊)

6. Y Gou, Y Zhang, ZL Zhang, J Wang, ZP Zhou, F Yang*, H Liang*. Design of an anticancer copper(II) pro-drug based on the Lys199 residue of the active targeting human serum albumin nanoparticle carrier. Molecular Pharmaceutics. 2017, 14: 1861-1873.

7. Qi JX, Zhang Y, Gou Y, Zhang ZL, Zhou ZP, Wu XY, Yang F*,Liang H*. Developing an anti-cancer copper(II) pro-drug based on the His242 residue of the human serum albumin carrier IIA sub-domain. Molecular Pharmaceutics. 2016, 13: 1501?1507.

8. Qi JX, Gou Y, Zhang Y, XY Wu, Yang F*,H Liang*. HSA-based multi-drug delivery systems for combination therapy of three anticancer agents. Molecular Pharmaceutics. 2016, 13: 3098-105.

9. Yang F, Yue J, Ma L, Ma Z, Li M, Wu X, Liang H*. Interactive associations of drug-drug and drug-drug-drug with IIA sub-domain of human serum albumin. Molecular Pharmaceutics. 2012, 9: 3259-65.

10.Jiang BP, Zhou B, Shen XC*, Yu YX, Ji SC, Wen CC, Liang H*. Selective Probing of Gaseous Ammonia Using Red-Emitting Carbon Dots Based on an Interfacial Response Mechanism. Eur Chem J. 2015, 21:18993-9.

 

综述:

1. Designing pro-drugs based on special residues of human serum albumin. Curr Top Med Chem. 2016, 16: 996-1008. (SCI 2)

2. Alkaloid-metal based anticancer agents. Curr Top Med Chem, 2013,13: 2104-2115.

3. Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: Development of HSA carrier for metal-based drugs. Curr Pharm Design. 2015, 21: 1848-61. (SCI 2)

 

专题评论 (Editorial Article):

1. HSA-based anti-inflammatory therapy: a new and improved approach. Future Med Chem. 2014, 6: 119-21. (SCI 2)

2. HSA IIA subdomain-based developing anticancer metal pro-drug: a new and improved approach. Future Med Chem. 2016, 8: 89-91.

3. HSA-based drug development and drug delivery systems. Curr Pharm Design. 2016, 21: 1784. (SCI 2)

 

 

科研项目

(1)广西院士后备培养人选 (2017.1-2021.12)

(2)国家自然科学基金-重点项目(21431001): 基于中药活性成分金属抗肿瘤配合物研究 (2015.1-2019.12)

(3)教育部创新团队:天然活性物质的发现、结构改造与功能

(4) 国家自然科学基金(21171043): 抗肿瘤先导植物药、金属基药物与人血清白蛋白相互作用研究 (2012.1-2015.12)

 

获奖情况

国家百千万人才工程领军人才(2016

英国皇家化学会会士(2015

中国青年科技奖(2001

国家有突出贡献的中青年专家(1999

广西十百千人才工程第一层次人选(1998

国家百千万人才工程人选1996

国务院政府特殊津贴(1996

 

XML 地图 | Sitemap 地图